XTLB – X.T.L. Biopharmaceuticals Ltd. ADR

Float Short %

0.13

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

1.35

Target Price

Analyst Recom

Performance Q

13.4

Relative Volume

0.11

Beta

1.15

Ticker: XTLB

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	XTLB	1.41	N/A	N/A	0
2025-08-18	XTLB	1.36	N/A	N/A	0
2025-08-19	XTLB	1.32	N/A	N/A	0
2025-08-20	XTLB	1.25	N/A	N/A	0
2025-08-21	XTLB	1.24	N/A	N/A	0
2025-08-22	XTLB	1.16	N/A	N/A	0
2025-08-25	XTLB	1.2258	N/A	N/A	0
2025-08-26	XTLB	1.18	N/A	N/A	0
2025-08-27	XTLB	1.17	N/A	N/A	0
2025-08-28	XTLB	1.11	N/A	N/A	0
2025-08-29	XTLB	1.23	N/A	N/A	0
2025-09-02	XTLB	1.19	N/A	N/A	0
2025-09-03	XTLB	1.2	N/A	N/A	0
2025-09-04	XTLB	1.25	N/A	N/A	0
2025-09-05	XTLB	1.2464	N/A	N/A	0
2025-09-08	XTLB	1.28	N/A	N/A	0
2025-09-09	XTLB	1.48	N/A	N/A	0
2025-09-10	XTLB	1.42	N/A	N/A	0
2025-09-11	XTLB	1.395	N/A	N/A	0
2025-09-12	XTLB	1.35	N/A	N/A	0
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	XTLB	1.42	-	-	-
2025-08-18	XTLB	1.36	-	-	-
2025-08-19	XTLB	1.32	-	-	-
2025-08-20	XTLB	1.30	-	-	-
2025-08-21	XTLB	1.26	-	-	-
2025-08-22	XTLB	1.17	-	-	-
2025-08-25	XTLB	1.20	-	-	-
2025-08-26	XTLB	1.18	-	-	-
2025-08-28	XTLB	1.23	-	-	-
2025-08-29	XTLB	1.23	-	-	-
2025-09-02	XTLB	1.26	-	-	-
2025-09-03	XTLB	1.19	-	-	-
2025-09-04	XTLB	1.19	-	-	-
2025-09-05	XTLB	1.25	-	-	-
2025-09-08	XTLB	1.29	-	-	-
2025-09-09	XTLB	1.49	-	-	-
2025-09-10	XTLB	1.50	-	-	-
2025-09-11	XTLB	1.39	-	-	-
2025-09-12	XTLB	1.35	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	XTLB	0.00	1.98	0.15
2025-08-18	XTLB	0.00	1.98	0.15
2025-08-19	XTLB	0.00	1.98	0.15
2025-08-20	XTLB	0.00	1.98	0.15
2025-08-21	XTLB	0.00	1.98	0.15
2025-08-22	XTLB	0.00	1.98	0.15
2025-08-25	XTLB	0.00	-88.50	0.15
2025-08-26	XTLB	0.00	-88.50	0.15
2025-08-27	XTLB	0.00	-88.50	0.16
2025-08-28	XTLB	0.00	-88.50	0.16
2025-08-29	XTLB	0.00	-88.50	0.16
2025-09-02	XTLB	0.00	-89.26	0.16
2025-09-03	XTLB	0.00	-89.26	0.16
2025-09-04	XTLB	0.00	-89.26	0.16
2025-09-05	XTLB	0.00	-89.26	0.16
2025-09-08	XTLB	0.00	-88.10	0.16
2025-09-09	XTLB	0.00	-88.10	0.16
2025-09-10	XTLB	0.00	-88.10	0.16
2025-09-11	XTLB	0.00	-88.10	0.13
2025-09-12	XTLB	0.00	-88.10	0.13
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-88.1

Beta

1.15

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

79.8

Max Drawdown 5-Year %

-85.4

Target Price

P/E

Forward P/E

PEG

P/S

26.42

P/B

2.19

P/Free Cash Flow

EPS

-0.11

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-227.72

Relative Volume

0.11

Return on Equity vs Sector %

-43.8

Return on Equity vs Industry %

-30.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

XTL Biopharmaceuticals Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 10

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

stock quote shares XTLB – X.T.L. Biopharmaceuticals Ltd. ADR Stock Price stock today

news today XTLB – X.T.L. Biopharmaceuticals Ltd. ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch XTLB – X.T.L. Biopharmaceuticals Ltd. ADR yahoo finance google finance

stock history XTLB – X.T.L. Biopharmaceuticals Ltd. ADR invest stock market

stock prices XTLB premarket after hours

ticker XTLB fair value insiders trading

XNCR – Xencor Inc

Float Short %

14.37

Margin Of Safety %

Put/Call OI Ratio

1.04

EPS Next Q Diff

-0.33

EPS Last/This Y

1.01

EPS This/Next Y

-0.26

Price

8.6

Target Price

24.1

Analyst Recom

1.5

Performance Q

-8.8

Relative Volume

1.09

Beta

0.88

Ticker: XNCR

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	XNCR	7.68	0.27	0.00	294
2025-08-18	XNCR	7.82	0.18	0.00	158
2025-08-19	XNCR	7.58	0.16	999.99	170
2025-08-20	XNCR	7.51	0.19	999.99	174
2025-08-21	XNCR	7.44	1.16	0.55	316
2025-08-22	XNCR	8.4	1.16	0.55	316
2025-08-25	XNCR	7.99	1.28	0.00	314
2025-08-26	XNCR	7.91	1.21	20.75	322
2025-08-27	XNCR	8.02	1.21	20.75	322
2025-08-28	XNCR	8.05	1.60	0.00	416
2025-08-29	XNCR	8.12	1.60	0.00	416
2025-09-02	XNCR	8.54	1.60	0.00	416
2025-09-03	XNCR	8.32	1.60	0.00	416
2025-09-04	XNCR	8.37	1.51	0.00	425
2025-09-05	XNCR	8.55	1.50	0.00	427
2025-09-08	XNCR	8.41	1.23	0.00	464
2025-09-09	XNCR	8.3	1.23	0.00	464
2025-09-10	XNCR	8.36	1.17	0.00	474
2025-09-11	XNCR	8.48	1.18	0.00	473
2025-09-12	XNCR	8.59	1.04	0.00	502
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	XNCR	7.68	-1.2	-	-2.58
2025-08-18	XNCR	7.81	0.0	-	-2.58
2025-08-19	XNCR	7.59	0.0	-	-2.58
2025-08-20	XNCR	7.51	0.0	-	-2.58
2025-08-21	XNCR	7.45	0.0	-	-2.58
2025-08-22	XNCR	8.41	0.0	-	-2.58
2025-08-25	XNCR	8.00	-0.4	-	-2.55
2025-08-26	XNCR	7.90	-0.4	-	-2.55
2025-08-28	XNCR	8.05	-0.4	-	-2.55
2025-08-29	XNCR	8.13	-0.4	-	-2.55
2025-09-02	XNCR	8.55	-0.4	-	-2.55
2025-09-03	XNCR	8.32	-0.4	-	-2.55
2025-09-04	XNCR	8.36	-0.4	-	-2.55
2025-09-05	XNCR	8.55	-0.4	-	-2.57
2025-09-08	XNCR	8.41	-0.4	-	-2.57
2025-09-09	XNCR	8.31	-0.4	-	-2.57
2025-09-10	XNCR	8.35	-0.4	-	-2.57
2025-09-11	XNCR	8.50	-0.4	-	-2.57
2025-09-12	XNCR	8.60	-0.4	-	-2.57
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	XNCR	-1.35	7.10	13.82
2025-08-18	XNCR	-1.35	7.95	13.82
2025-08-19	XNCR	-1.35	7.95	13.82
2025-08-20	XNCR	-1.35	7.95	13.82
2025-08-21	XNCR	-1.35	7.95	13.82
2025-08-22	XNCR	-1.35	7.95	13.82
2025-08-25	XNCR	-1.35	5.61	13.82
2025-08-26	XNCR	-1.35	5.61	13.82
2025-08-27	XNCR	-1.35	5.61	14.23
2025-08-28	XNCR	-1.35	5.61	14.23
2025-08-29	XNCR	-1.35	5.61	14.23
2025-09-02	XNCR	-1.35	5.58	14.21
2025-09-03	XNCR	-1.38	5.58	14.21
2025-09-04	XNCR	-1.38	5.58	14.21
2025-09-05	XNCR	-1.38	5.58	14.21
2025-09-08	XNCR	-1.38	5.61	14.21
2025-09-09	XNCR	-1.38	5.61	14.21
2025-09-10	XNCR	-1.38	5.61	14.21
2025-09-11	XNCR	-1.35	5.61	14.37
2025-09-12	XNCR	-0.51	5.61	14.37
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.41

Avg. EPS Est. Current Quarter

-0.71

Avg. EPS Est. Next Quarter

-0.74

Insider Transactions

-0.51

Institutional Transactions

5.61

Beta

0.88

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

85.3

Max Drawdown 5-Year %

-87

Target Price

24.1

P/E

Forward P/E

PEG

P/S

4.17

P/B

0.99

P/Free Cash Flow

EPS

-2.42

Average EPS Est. Cur. Y

-2.57

EPS Next Y. (Est.)

-2.83

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-116.44

Relative Volume

1.09

Return on Equity vs Sector %

-52.5

Return on Equity vs Industry %

-39.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.36

EBIT Estimation

Xencor, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 250

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

stock quote shares XNCR – Xencor Inc Stock Price stock today

news today XNCR – Xencor Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch XNCR – Xencor Inc yahoo finance google finance

stock history XNCR – Xencor Inc invest stock market

stock prices XNCR premarket after hours

ticker XNCR fair value insiders trading

TARS – Tarsus Pharmaceuticals Inc

Float Short %

17.95

Margin Of Safety %

Put/Call OI Ratio

0.08

EPS Next Q Diff

0.45

EPS Last/This Y

1.57

EPS This/Next Y

1.53

Price

49.33

Target Price

73.71

Analyst Recom

1.25

Performance Q

20.54

Relative Volume

1.88

Beta

0.81

Ticker: TARS

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	TARS	54.22	4.63	0.00	3391
2025-08-18	TARS	54.65	0.12	0.00	561
2025-08-19	TARS	53.7	0.13	0.00	566
2025-08-20	TARS	55.46	0.12	1.59	570
2025-08-21	TARS	56.56	0.19	0.08	627
2025-08-22	TARS	57.24	0.18	0.22	678
2025-08-25	TARS	56.64	0.16	0.00	687
2025-08-26	TARS	58.85	0.16	0.00	694
2025-08-27	TARS	57.78	0.16	0.00	692
2025-08-28	TARS	58.12	0.16	0.13	691
2025-08-29	TARS	58.53	0.16	0.00	693
2025-09-02	TARS	58.58	0.16	0.00	695
2025-09-03	TARS	57.7	0.16	0.00	696
2025-09-04	TARS	57.4	0.16	0.70	696
2025-09-05	TARS	57.6	0.17	0.00	682
2025-09-08	TARS	56.65	0.09	0.10	1249
2025-09-09	TARS	56.48	0.08	0.00	1246
2025-09-10	TARS	54.57	0.08	0.50	1267
2025-09-11	TARS	51.88	0.08	0.26	1268
2025-09-12	TARS	49.33	0.08	0.02	1270
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	TARS	54.21	42.6	-	-1.52
2025-08-18	TARS	54.57	42.6	-	-1.52
2025-08-19	TARS	53.70	42.2	-	-1.50
2025-08-20	TARS	55.47	42.2	-	-1.50
2025-08-21	TARS	56.55	42.2	-	-1.50
2025-08-22	TARS	57.19	42.2	-	-1.50
2025-08-25	TARS	56.63	42.2	-	-1.50
2025-08-26	TARS	58.85	42.2	-	-1.50
2025-08-28	TARS	58.16	42.2	-	-1.50
2025-08-29	TARS	58.58	42.2	-	-1.50
2025-09-02	TARS	58.60	42.2	-	-1.50
2025-09-03	TARS	57.69	42.2	-	-1.50
2025-09-04	TARS	57.40	42.2	-	-1.50
2025-09-05	TARS	57.63	42.2	-	-1.50
2025-09-08	TARS	56.89	42.2	-	-1.50
2025-09-09	TARS	56.49	42.2	-	-1.50
2025-09-10	TARS	54.35	42.2	-	-1.50
2025-09-11	TARS	51.87	42.2	-	-1.50
2025-09-12	TARS	49.33	42.2	-	-1.50
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	TARS	-2.74	8.09	21.17
2025-08-18	TARS	-2.74	8.92	21.10
2025-08-19	TARS	-2.84	8.92	21.10
2025-08-20	TARS	-2.84	8.92	21.10
2025-08-21	TARS	-2.84	8.92	21.10
2025-08-22	TARS	-2.84	8.92	21.10
2025-08-25	TARS	-2.84	9.71	21.10
2025-08-26	TARS	-2.84	9.71	21.10
2025-08-27	TARS	-2.84	9.71	19.04
2025-08-28	TARS	-2.84	9.71	19.04
2025-08-29	TARS	-2.84	9.71	19.04
2025-09-02	TARS	-2.84	9.71	19.04
2025-09-03	TARS	-2.84	9.71	19.04
2025-09-04	TARS	-2.84	9.71	19.04
2025-09-05	TARS	-2.84	9.71	19.04
2025-09-08	TARS	-2.84	9.81	19.04
2025-09-09	TARS	-2.84	9.81	19.04
2025-09-10	TARS	-3.53	9.81	19.04
2025-09-11	TARS	-3.55	9.81	17.95
2025-09-12	TARS	-3.55	9.81	17.95
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.48

Avg. EPS Est. Current Quarter

-0.35

Avg. EPS Est. Next Quarter

-0.03

Insider Transactions

-3.55

Institutional Transactions

9.81

Beta

0.81

Average Sales Estimate Current Quarter

113

Average Sales Estimate Next Quarter

131

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

22.5

Max Drawdown 5-Year %

Target Price

73.71

P/E

Forward P/E

50.74

PEG

P/S

7.05

P/B

6.26

P/Free Cash Flow

EPS

-2.33

Average EPS Est. Cur. Y

-1.5

EPS Next Y. (Est.)

0.03

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-31.13

Relative Volume

1.88

Return on Equity vs Sector %

-52.5

Return on Equity vs Industry %

-39.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.43

EBIT Estimation

Tarsus Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 323

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

stock quote shares TARS – Tarsus Pharmaceuticals Inc Stock Price stock today

news today TARS – Tarsus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch TARS – Tarsus Pharmaceuticals Inc yahoo finance google finance

stock history TARS – Tarsus Pharmaceuticals Inc invest stock market

stock prices TARS premarket after hours

ticker TARS fair value insiders trading

SPRO – Spero Therapeutics, Inc.

Float Short %

1.31

Margin Of Safety %

Put/Call OI Ratio

0.35

EPS Next Q Diff

-0.19

EPS Last/This Y

0.81

EPS This/Next Y

0.43

Price

1.9

Target Price

Analyst Recom

Performance Q

-34.26

Relative Volume

0.46

Beta

1.49

Ticker: SPRO

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	SPRO	1.91	0.47	0.08	12429
2025-08-18	SPRO	1.905	0.50	0.00	11518
2025-08-19	SPRO	1.835	0.50	0.00	11581
2025-08-20	SPRO	1.84	0.49	0.00	11646
2025-08-21	SPRO	1.855	0.49	0.00	11677
2025-08-22	SPRO	1.875	0.49	7.77	11678
2025-08-25	SPRO	1.855	0.48	0.00	11581
2025-08-26	SPRO	1.86	0.47	0.00	11681
2025-08-27	SPRO	1.985	0.47	0.00	11680
2025-08-28	SPRO	2.005	0.46	0.00	11779
2025-08-29	SPRO	2.07	0.46	0.44	11859
2025-09-02	SPRO	2.06	0.46	0.20	11885
2025-09-03	SPRO	2.08	0.46	3.85	11896
2025-09-04	SPRO	2.14	0.47	0.00	12021
2025-09-05	SPRO	2.16	0.47	0.13	12022
2025-09-08	SPRO	2	0.47	0.00	12031
2025-09-09	SPRO	1.99	0.47	0.00	12082
2025-09-10	SPRO	1.93	0.47	0.00	12116
2025-09-11	SPRO	1.95	0.35	0.00	11308
2025-09-12	SPRO	1.905	0.35	6.57	11318
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	SPRO	1.90	-	-	-0.79
2025-08-18	SPRO	1.90	21.9	-	-0.79
2025-08-19	SPRO	1.84	21.9	-	-0.79
2025-08-20	SPRO	1.84	21.9	-	-0.79
2025-08-21	SPRO	1.85	21.9	-	-0.79
2025-08-22	SPRO	1.87	-	-	-0.79
2025-08-25	SPRO	1.85	-	-	-0.79
2025-08-26	SPRO	1.85	-	-	-0.79
2025-08-28	SPRO	2.00	-	-	-0.79
2025-08-29	SPRO	2.07	-	-	-0.79
2025-09-02	SPRO	2.05	-	-	-0.46
2025-09-03	SPRO	2.08	-	-	-0.46
2025-09-04	SPRO	2.13	-	-	-0.46
2025-09-05	SPRO	2.15	-	-	-0.46
2025-09-08	SPRO	2.00	-	-	-0.46
2025-09-09	SPRO	1.99	-	-	-0.46
2025-09-10	SPRO	1.92	-	-	-0.46
2025-09-11	SPRO	1.95	-	-	-0.46
2025-09-12	SPRO	1.90	-	-	-0.46
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	SPRO	0.00	-3.62	3.68
2025-08-18	SPRO	0.00	-5.77	3.65
2025-08-19	SPRO	0.00	-5.77	3.65
2025-08-20	SPRO	0.00	-5.77	3.65
2025-08-21	SPRO	0.00	-5.77	3.65
2025-08-22	SPRO	0.00	-5.77	3.65
2025-08-25	SPRO	0.00	-26.37	3.65
2025-08-26	SPRO	0.00	-26.37	3.65
2025-08-27	SPRO	0.00	-26.37	2.45
2025-08-28	SPRO	0.00	-26.37	2.45
2025-08-29	SPRO	0.00	-26.37	2.45
2025-09-02	SPRO	0.00	-26.37	2.45
2025-09-03	SPRO	-0.04	-26.37	2.45
2025-09-04	SPRO	-0.04	-26.37	2.45
2025-09-05	SPRO	-0.04	-26.37	2.40
2025-09-08	SPRO	-0.05	-26.41	2.40
2025-09-09	SPRO	-0.05	-26.41	2.40
2025-09-10	SPRO	-0.05	-26.41	2.40
2025-09-11	SPRO	-0.05	-26.41	1.31
2025-09-12	SPRO	-0.05	-26.41	1.31
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.03

Avg. EPS Est. Current Quarter

-0.25

Avg. EPS Est. Next Quarter

-0.22

Insider Transactions

-0.05

Institutional Transactions

-26.41

Beta

1.49

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

91.9

Max Drawdown 5-Year %

-97.5

Target Price

P/E

Forward P/E

PEG

P/S

3.14

P/B

3.25

P/Free Cash Flow

EPS

-0.98

Average EPS Est. Cur. Y

-0.46

EPS Next Y. (Est.)

-0.04

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-157.24

Relative Volume

0.46

Return on Equity vs Sector %

-188.2

Return on Equity vs Industry %

-175

EPS 1 7Days Diff

0.3

EPS 1 30Days Diff

0.69

EBIT Estimation

Spero Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 32

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

stock quote shares SPRO – Spero Therapeutics, Inc. Stock Price stock today

news today SPRO – Spero Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch SPRO – Spero Therapeutics, Inc. yahoo finance google finance

stock history SPRO – Spero Therapeutics, Inc. invest stock market

stock prices SPRO premarket after hours

ticker SPRO fair value insiders trading

SLNO – Soleno Therapeutics Inc

Float Short %

16.48

Margin Of Safety %

Put/Call OI Ratio

1.12

EPS Next Q Diff

0.29

EPS Last/This Y

3.7

EPS This/Next Y

3.7

Price

53.64

Target Price

118.73

Analyst Recom

1.09

Performance Q

-33.14

Relative Volume

2.04

Beta

-2.76

Ticker: SLNO

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	SLNO	71.64	1.07	1.89	38227
2025-08-18	SLNO	68.1	1.27	0.54	35615
2025-08-19	SLNO	66.8	1.23	0.58	37403
2025-08-20	SLNO	68.9	1.23	0.95	37506
2025-08-21	SLNO	69.78	1.22	1.96	38429
2025-08-22	SLNO	68.61	1.23	1.88	38788
2025-08-25	SLNO	66.46	1.23	0.35	38898
2025-08-26	SLNO	69.58	1.19	0.09	38205
2025-08-27	SLNO	67.32	1.19	1.72	38270
2025-08-28	SLNO	68.38	1.23	0.04	39086
2025-08-29	SLNO	67.27	1.21	2.67	38891
2025-09-02	SLNO	67.19	1.21	0.15	38888
2025-09-03	SLNO	66.9	1.21	0.04	38923
2025-09-04	SLNO	69.51	1.21	6.36	38949
2025-09-05	SLNO	69.74	1.23	0.03	39444
2025-09-08	SLNO	72.3	1.22	10.09	39673
2025-09-09	SLNO	69.85	1.22	0.01	39668
2025-09-10	SLNO	60.01	1.20	0.84	39977
2025-09-11	SLNO	56.68	1.15	0.81	47665
2025-09-12	SLNO	53.66	1.12	0.57	50335
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	SLNO	71.68	-	-	0.00
2025-08-18	SLNO	68.07	-	-	0.00
2025-08-19	SLNO	66.81	-	-	-0.81
2025-08-20	SLNO	69.00	-	-	-0.81
2025-08-21	SLNO	69.79	-	-	-0.80
2025-08-22	SLNO	68.53	-	-	-0.80
2025-08-25	SLNO	66.45	-	-	-0.70
2025-08-26	SLNO	69.61	-	-	-0.70
2025-08-28	SLNO	68.41	-	-	-0.70
2025-08-29	SLNO	67.57	-	-	-0.70
2025-09-02	SLNO	67.21	-	-	-0.70
2025-09-03	SLNO	66.97	-	-	-0.70
2025-09-04	SLNO	69.52	-	-	-0.70
2025-09-05	SLNO	69.77	-	-	-0.69
2025-09-08	SLNO	72.30	-	-	-0.69
2025-09-09	SLNO	70.18	-	-	-0.69
2025-09-10	SLNO	60.22	-	-	-0.69
2025-09-11	SLNO	56.72	-	-	-0.69
2025-09-12	SLNO	53.64	-	-	-0.69
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	SLNO	-25.59	10.88	13.55
2025-08-18	SLNO	-25.59	30.37	13.30
2025-08-19	SLNO	-27.62	30.37	13.14
2025-08-20	SLNO	-29.14	30.37	13.14
2025-08-21	SLNO	-29.14	30.37	13.14
2025-08-22	SLNO	-29.13	30.37	13.14
2025-08-25	SLNO	-29.13	13.78	13.14
2025-08-26	SLNO	-29.13	13.78	13.14
2025-08-27	SLNO	-29.13	13.78	13.72
2025-08-28	SLNO	-29.13	13.78	13.72
2025-08-29	SLNO	-29.13	13.78	13.72
2025-09-02	SLNO	-29.13	13.83	13.72
2025-09-03	SLNO	-29.13	13.83	13.72
2025-09-04	SLNO	-29.13	13.83	13.72
2025-09-05	SLNO	-29.13	13.83	13.72
2025-09-08	SLNO	-29.13	13.98	13.72
2025-09-09	SLNO	-29.13	13.98	13.72
2025-09-10	SLNO	-29.13	13.98	13.72
2025-09-11	SLNO	-29.13	13.98	16.49
2025-09-12	SLNO	-29.13	13.98	16.48
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.09

Avg. EPS Est. Current Quarter

0.05

Avg. EPS Est. Next Quarter

0.2

Insider Transactions

-29.13

Institutional Transactions

13.98

Beta

-2.76

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

40.6

Max Drawdown 5-Year %

-98.2

Target Price

118.73

P/E

Forward P/E

17.85

PEG

P/S

87.25

P/B

11.26

P/Free Cash Flow

EPS

-4.15

Average EPS Est. Cur. Y

-0.69

EPS Next Y. (Est.)

3.01

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-554.49

Relative Volume

2.04

Return on Equity vs Sector %

-100.3

Return on Equity vs Industry %

-87.1

EPS 1 7Days Diff

EPS 1 30Days Diff

1.14

EBIT Estimation

Soleno Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 133

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

stock quote shares SLNO – Soleno Therapeutics Inc Stock Price stock today

news today SLNO – Soleno Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch SLNO – Soleno Therapeutics Inc yahoo finance google finance

stock history SLNO – Soleno Therapeutics Inc invest stock market

stock prices SLNO premarket after hours

ticker SLNO fair value insiders trading

SEEL – Seelos Therapeutics Inc

Float Short %

46.13

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

989.44

EPS This/Next Y

Price

0.39

Target Price

Analyst Recom

Performance Q

-85.02

Relative Volume

Beta

1.87

Ticker: SEEL

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	SEEL	0.39	N/A	N/A	0
2025-08-18	SEEL	0.39	N/A	N/A	0
2025-08-19	SEEL	0.39	N/A	N/A	0
2025-08-20	SEEL	0.39	N/A	N/A	0
2025-08-21	SEEL	0.39	N/A	N/A	0
2025-08-22	SEEL	0.39	N/A	N/A	0
2025-08-25	SEEL	0.39	N/A	N/A	0
2025-08-26	SEEL	0.39	N/A	N/A	0
2025-08-27	SEEL	0.39	N/A	N/A	0
2025-08-28	SEEL	0.39	N/A	N/A	0
2025-08-29	SEEL	0.39	N/A	N/A	0
2025-09-02	SEEL	0.39	N/A	N/A	0
2025-09-03	SEEL	0.39	N/A	N/A	0
2025-09-04	SEEL	0.39	N/A	N/A	0
2025-09-05	SEEL	0.39	N/A	N/A	0
2025-09-08	SEEL	0.39	N/A	N/A	0
2025-09-09	SEEL	0.39	N/A	N/A	0
2025-09-10	SEEL	0.39	N/A	N/A	0
2025-09-11	SEEL	0.39	N/A	N/A	0
2025-09-12	SEEL	0.39	N/A	N/A	0
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-1.48

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

1.87

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

100

Max Drawdown 5-Year %

-100

Target Price

P/E

Forward P/E

PEG

P/S

0.37

P/B

P/Free Cash Flow

EPS

351.04

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

-33.1

Return on Equity vs Industry %

-20.9

EPS 1 7Days Diff

4.1

EPS 1 30Days Diff

4.09

EBIT Estimation

stock quote shares SEEL – Seelos Therapeutics Inc Stock Price stock today

news today SEEL – Seelos Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch SEEL – Seelos Therapeutics Inc yahoo finance google finance

stock history SEEL – Seelos Therapeutics Inc invest stock market

stock prices SEEL premarket after hours

ticker SEEL fair value insiders trading

No more stocks to show

XTLB – X.T.L. Biopharmaceuticals Ltd. ADR

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: XTLB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

XNCR – Xencor Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: XNCR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y